The San Diego Union-Tribune Spotlights the Early Vision Behind Model Medicines
Press Coverage
Patrick ONeill
The San Diego Union-Tribune profiled the company then known as Repurpose.AI, capturing an early chapter in what would become Model Medicines’ broader AI-driven drug discovery platform.
Patrick ONeill
Head of Partnerships and Investor Relations
Before its rebrand to Model Medicines, the company was featured in The San Diego Union-Tribune for its early work applying artificial intelligence to therapeutic discovery. The article highlighted the company’s foundational thesis: that advanced machine learning could uncover overlooked therapeutic opportunities, accelerate development timelines, and help identify promising drug candidates with greater speed and precision.
The feature also covered the company’s collaboration with LEO Pharma, focused on identifying and validating potential treatments for inflammatory and dermatology indications. While the company’s earliest work included evaluating known and clinically characterized compounds, the article captured a broader ambition already taking shape — building an AI-native discovery company capable of expanding into new therapeutic areas and advancing a differentiated pipeline of medicines.
